Clever Culture Systems Secures Two Orders for Imaging Instrument

MT Newswires Live
05/28

Clever Culture Systems (ASX:CC5) secured two new pharmaceutical orders, including an agreement for a paid evaluation of its APAS Independence imaging instrument with a new pharmaceutical customer, according to a Thursday filing with the Australian bourse.

The agreement includes an upfront payment covering installation, which is expected in June, and a non-refundable prepayment for a potential purchase following the evaluation, the company said.

The second purchase order is from a new single-site US customer. The instrument under the second order has been shipped and is also due to be installed in June.

Clever Culture said the volume of active global top-20 pharma customers deploying APAS increased in fiscal year 2026 and is expected to grow further in fiscal year 2027.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10